Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Luke F. Peterson, Hanshi Sun, Yihong Liu, Harish Potu, Malathi Kandarpa, Monika Ermann, Stephen M. Courtney, Matthew Young, Hollis D. Showalter, Duxin Sun, Andrzej Jakubowiak, Sami N. Malek, Moshe Talpaz, Nicholas J. Donato

Blood (2015) 125 (23): 3588–3597.

https://doi.org/10.1182/blood-2014-10-605584

Published: 2015

Includes: Supplemental data

Journal Articles

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

Luke F. Peterson, PhD, Hanshi Sun, PhD, Yihong Liu, PhD, Malathi Kandarpa, PhD, Diane Giannola, Jessica Mercer, PhD, Hollis D. Showalter, Ph.D., Andrzej Jakubowiak, MD, PhD, Moshe Talpaz, MD, Nicholas J. Donato, PhD

Blood (2012) 120 (21): 2936.

https://doi.org/10.1182/blood.V120.21.2936.2936

Published: 2012

Journal Articles

Mechanism of Action of a Small Molecule Inhibitor That Targets Usp9x Deubiquitinase Activity in Multiple Myeloma and Mantle Cell Lymphoma

Luke F. Peterson, PhD, Hanshi Sun, PhD, Matthew Young, PhD, Hollis D. Showalter, Ph.D., Andrzej J Jakubowiak, MD, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD

Blood (2011) 118 (21): 1415.

https://doi.org/10.1182/blood.V118.21.1415.1415

Published: 2011

Journal Articles

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

Luke F. Peterson, PhD, Hanshi Sun, PhD, Vaibhav Kapuria, Ph.D., Malathi Kandarpa, PhD, Moshe Talpaz, MD, Andrzej J Jakubowiak, MD, PhD, Nicholas Donato, PhD

Blood (2011) 118 (21): 1835.

https://doi.org/10.1182/blood.V118.21.1835.1835

Published: 2011

Journal Articles

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

Hanshi Sun, Vaibhav Kapuria, Luke F. Peterson, Dexing Fang, William G. Bornmann, Geoffrey Bartholomeusz, Moshe Talpaz, Nicholas J. Donato

Blood (2011) 117 (11): 3151–3162.

https://doi.org/10.1182/blood-2010-03-276477

Published: 2011

Includes: Supplemental data

Journal Articles

Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma

Hanshi Sun, PhD, Vaibhav Kapuria, Ph.D., Luke F. Peterson, PhD, Diane Giannola, Kandarpa Malathi, Ph.D., Moshe Talpaz, MD, Andrzej J Jakubowiak, MD, PhD, Nicholas Donato, PhD

Blood (2010) 116 (21): 3005.

https://doi.org/10.1182/blood.V116.21.3005.3005

Published: 2010

Journal Articles

The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML).

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermeglia, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Matthew Young, PhD, Hanshi Sun, PhD, Luke F. Peterson, PhD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD

Blood (2010) 116 (21): 3402.

https://doi.org/10.1182/blood.V116.21.3402.3402

Published: 2010

Journal Articles

WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.

Nicholas J Donato, Ph.D., Hanshi Sun, Ph.D., Vaibhav Kapuria, Luke F Peterson, PhD, Geoffrey Bartholomeusz, Ph.D., William G. Bornmann, Ph.D., Moshe Talpaz, M.D.

Blood (2009) 114 (22): 3303.

https://doi.org/10.1182/blood.V114.22.3303.3303

Published: 2009

Journal Articles

Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors

Luke F Peterson, PhD, Hanshi Sun, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, David Maxwell, PhD, Nicholas Donato, Moshe Talpaz

Blood (2008) 112 (11): 3212.

https://doi.org/10.1182/blood.V112.11.3212.3212

Published: 2008

Journal Articles

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

Nicholas Donato, PhD, Vaibhav Kapuria, MS, Hanshi Sun, PhD, David Maxwell, PhD, Geoffrey Bartholomeusz, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, Moshe Talpaz, MD

Blood (2007) 110 (11): 1003.

https://doi.org/10.1182/blood.V110.11.1003.1003

Published: 2007

NARROW

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

Mechanism of Action of a Small Molecule Inhibitor That Targets Usp9x Deubiquitinase Activity in Multiple Myeloma and Mantle Cell Lymphoma

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma

The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML).

WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.

Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only